CD44 and head and neck squamous cell carcinoma: For instance, we demonstrated that HNC0014 pretreatment re-sensitized Exosp-transformed HNSCC cells to cisplatin and reduced the expression of STAT3, PD-L1, c-Met, CD44, β-catenin, and the phosphorylated forms of c-Met/STAT3.